Novo Nordisk wants US Ozempic lawsuit dismissed
Novo Nordisk’s lawyers are questioning a private lawsuit filed against the company by a woman who claims to have suffered serious injuries from the use of the GLP-1 analog Ozempic, used to treat diabetes, Bloomberg News reports.
The allegations come from Jaclyn Bjorklund, but Novo Nordisk does not believe that the federal court in Louisiana, where the case has been filed, has jurisdiction over the Danish company because no connections between the state of Louisiana and Novo Nordisk have been identified in the lawsuit.
The company also believes that Jaclyn Bjorklund has failed to provide basic information about her history and alleged injuries from the use of Ozempic.
Therefore, the Danish pharmaceutical company wants the case dropped.
Jaclyn Bjorklund also claims to have suffered similar injuries from the use of the rival drug Mounjaro from Eli Lilly.
